Structural Modifications IGF-1 LR3 was specifically designed to overcome this limitation through two strategic structural modifications: First, the peptide contains an N-terminal extension of 13 amino acids (adding glutamic acid residues), bringing the total length to 83 amino acids instead of 70, which sterically interferes with IGFBP binding
Pay attention to a few key points, especially regarding alcohol use during therapy
So be explicit with patients and with yourself: physicians prescribing now based on the April Category 2 removal are operating without a clear legal compounding framework
If you are already on tirzepatide and doing well, there is no medical reason to wait for something else
Yilmaz B, Terekeci H, Sandal S, Kelestimur F (2020) Endocrine disrupting chemicals: exposure, effects on human health, mechanism of action, models for testing and strategies for prevention